Wiegmann K, Muthyala S, Kim D H, Arnason B G, Chelmicka-Schorr E
Department of Neurology, University of Chicago, IL 60637.
J Neuroimmunol. 1995 Feb;56(2):201-6. doi: 10.1016/0165-5728(94)00153-f.
Chronic/relapsing experimental allergic encephalomyelitis (CREAE) serves as an animal model for relapsing/remitting multiple sclerosis. Treatment with the beta-adrenergic agonist isoproterenol or the beta 2-adrenergic agonist terbutaline significantly suppressed both the first acute attack and the number of relapses in CREAE Lewis rats. The number of relapses was decreased even when treatment with beta-adrenergic agonist was started after the onset of the first acute attack of CREAE. beta-adrenergic receptor number was increased significantly on splenocytes from CREAE rats as compared to healthy controls or CFA-injected rats. Terbutaline treatment of CREAE rats lowered the splenocyte receptor number to normal values.
